<DOC>
	<DOCNO>NCT00100789</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy , gemcitabine paclitaxel , work different way stop growth tumor cell , either kill cell stop divide . Giving gemcitabine together paclitaxel may kill tumor cell . PURPOSE : This phase II trial study well give gemcitabine together paclitaxel work treat patient persistent , recurrent , metastatic head neck cancer .</brief_summary>
	<brief_title>S0329 , Gemcitabine Paclitaxel Treating Patients With Persistent , Recurrent , Metastatic Head Neck Cancer</brief_title>
	<detailed_description>OBJECTIVES : - Determine overall progression-free survival probability patient persistent , recurrent , metastatic squamous cell carcinoma head neck treat gemcitabine paclitaxel . - Determine confirm unconfirmed response ( partial complete ) probability patient measurable disease treat regimen . - Determine toxicity regimen patient . OUTLINE : This multicenter study . Patients receive gemcitabine IV 30 minute paclitaxel IV 1 hour day 1 15 . Courses repeat every 28 day absence disease progression unacceptable toxicity . Patients complete response ( CR ) receive 4 additional course beyond CR . Patients follow every 8 week disease progression , every 6 month 2 year , annually 1 year . PROJECTED ACCRUAL : A total 65 patient accrue study within 10-13 month .</detailed_description>
	<mesh_term>Head Neck Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically cytologically confirm squamous cell carcinoma head neck ( SCCHN ) Recurrent , persistent , newly diagnose metastatic disease Measurable nonmeasurable disease No active prior CNS metastasis PATIENT CHARACTERISTICS : Age 18 Performance status Zubrod 01 Life expectancy Not specify Hematopoietic Not specify Hepatic Not specify Renal Not specify Other No serious organ dysfunction No serious comorbid condition would preclude study treatment No history hypersensitivity reaction product contain polysorbate 80 No active infection require systemic antibiotic therapy No symptomatic sensory neuropathy â‰¥ grade 2 No malignancy within past 5 year except adequately treat basal cell squamous cell skin cancer carcinoma situ cervix Not pregnant nursing Fertile patient must use effective contraception PRIOR CONCURRENT THERAPY : Biologic therapy No concurrent biologic immunotherapy SCCHN No concurrent gene therapy SCCHN Chemotherapy No prior chemotherapy recurrent newly diagnose metastatic disease At least 6 month since prior induction adjuvant chemotherapy No 1 prior induction adjuvant regimen No prior gemcitabine taxanes part induction , adjuvant , neoadjuvant chemotherapy No concurrent chemotherapy SCCHN Endocrine therapy Not specify Radiotherapy At least 28 day since prior radiotherapy recover No concurrent radiotherapy SCCHN Surgery Not specify Other No concurrent therapy SCCHN</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2012</verification_date>
	<keyword>Recurrent</keyword>
	<keyword>stage IV</keyword>
	<keyword>squamous cell carcinoma</keyword>
	<keyword>hypopharynx</keyword>
	<keyword>larynx</keyword>
	<keyword>lip</keyword>
	<keyword>oral cavity</keyword>
	<keyword>nasopharynx</keyword>
	<keyword>oropharynx</keyword>
	<keyword>paranasal</keyword>
	<keyword>nasal cavity</keyword>
	<keyword>metastatic</keyword>
	<keyword>neck cancer</keyword>
</DOC>